Interferon-α counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer

Carcinogenesis

Volumn 30, Issue 5, 2009, Pages 851-860

  Persano, Luca ^a   Moserle, Lidia ^a   Esposito, Giovanni ^b   Bronte, Vincenzo ^b   Barbieri, Vito ^a   Iafrate, Massimo ^a   Gardiman, Marina P ^c   Larghero, Patrizia ^d   Pfeffer, Ulrich ^d   Naschberger, Elisabeth ^e   Stürzl, Michael ^e   Indraccolo, Stefano ^b   Amadori, Alberto ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e Division of Molecular and Experimental Surgery   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CXCL11 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN 1; LENTIVIRUS VECTOR; MYXOVIRUS RESISTANCE PROTEIN A; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IN VIVO GENE TRANSFER; INTERFERON PRODUCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; TUMOR REGRESSION; UPREGULATION;

CELL DIVISION; GTP-BINDING PROTEINS; HUMANS; INTERFERON-ALPHA; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATECTOMY; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 65549086161     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp052     Document Type: Article

References (51)

1. Minuzzo,S. et al. (2007) Angiogenesis meets immunology: Cytokine gene therapy of cancer. Mol. Aspects Med., 28, 59-86.
2. Sidky,Y.A. et al. (1987) Inhibition of angiogenesis by interferons: Effects on tumor- and lymphocyte-induced vascular responses. Cancer Res., 47, 5155-5161.
3. Rozera,C. et al. (1999) Interferon (IFN)-beta gene transfer into TS/A adenocarcinoma cells and comparison with IFN-alpha: Differential effects on tumorigenicity and host response. Am. J. Pathol., 154, 1211-1222.
4. Indraccolo,S. et al. (2002) Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells. Gene Ther., 9, 867-878.
5. Albini,A. et al. (2000) Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach. Am. J. Pathol., 156, 1381-1393.
6. Singh,R.K. et al. (1995) Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl Acad. Sci. USA, 92, 4562-4566.
7. von Marschall,Z. et al. (2003) Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl Cancer Inst., 95, 437-448.
8. Oliveira,I.C. et al. (1992) Downregulation of interleukin 8 gene expression in human fibroblasts: Unique mechanism of transcriptional inhibition by interferon. Proc. Natl Acad. Sci. USA, 89, 9049-9053.
9. Indraccolo,S. et al. (2007) Identification of genes selectively regulated by IFNs in endothelial cells. J. Immunol., 178, 1122-1135.
10. Huang,S.F. et al. (2002) Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel. Cancer Res., 62, 5720-5726.
11. Dong,Z. et al. (1999) Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. Cancer Res., 59, 872-879.
12. Zhang,F. et al. (2002) Tumor-infiltrating macrophages are involved in suppressing growth and metastasis of human prostate cancer cells by INF-beta gene therapy in nude mice. Clin. Cancer Res., 8, 2942-2951.
13. Cao,G. et al. (2001) Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice. Cancer Gene Ther., 8, 497-505.
14. Royuela,M. et al. (2000) Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: Parallelism with c-myc and p53 expression. Eur. Cytokine Netw., 11, 119-127.
15. Greenberg,N.M. et al. (1995) Prostate cancer in a transgenic mouse. Proc. Natl Acad. Sci. USA, 92, 3439-3443.
16. Huss,W.J. et al. (2001) Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res., 61, 2736-2743.
17. Bergers,G. et al. (2003) Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer, 3, 401-410.
18. Pallares,J. et al. (2006) Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol. Histopathol., 21, 857-865.
19. Viacava,P. et al. (2004) Angiogenesis and VEGF expression in pre-invasive lesions of the human breast. J. Pathol., 204, 140-146.
20. Becker,C.M. et al. (2002) Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1. Cancer Biol. Ther., 1, 548-553.
21. Huss,W.J. et al. (2003) SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis. Mol. Cancer Ther., 2 611-616.
22. Isayeva,T. et al. (2007) Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res., 67, 5789-5797.
23. Indraccolo,S. et al. (2005) Interferon-alpha gene therapy by lentiviral vectors contrasts ovarian cancer growth through angiogenesis inhibition. Hum. Gene Ther., 16, 957-970.
24. Indraccolo,S. et al. (2002) Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. Cancer Res. 62, 6099-6107.
25. Lubeseder-Martellato,C. et al. (2002) Guanylate-binding protein-1 expression is selectively induced by inflammatory cytokines and is an activation marker of endothelial cells during inflammatory diseases. Am. J. Pathol., 161, 1749-1759.
26. Flohr,F. et al. (1999) The central interactive region of human MxA GTPase is involved in GTPase activation and interaction with viral target structures. FEBS Lett., 463, 24-28.
27. Gariglio,M. et al. (1998) The murine homolog of the HIN 200 family, Ifi 204, is constitutively expressed in myeloid cells and selectively induced in the monocyte/macrophage lineage. J. Leukoc. Biol., 64, 608-614.
28. Indraccolo,S. et al. (2006) Gene therapy of ovarian cancer with IFN-alpha-producing fibroblasts: Comparison of constitutive and inducible vectors. Gene Ther., 13, 953-965.
29. Jain,R.K. (2003) Molecular regulation of vessel maturation. Nat. Med. 9, 685-693.
30. Sun,A. et al. (2008) Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression. Prostate, 68, 453-461.
31. Busk,P.K. et al. (2005) Cyclin D2 induces proliferation of cardiac myocytes and represses hypertrophy. Exp. Cell Res., 304, 149-161.
32. Cheng,Y.S. et al. (1983) Interferon induction of fibroblast proteins with guanylate binding activity. J. Biol. Chem., 258 7746-7750.
33. Nakaji,M. et al. (2004) IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat. Carcinogenesis, 25, 389-397.
34. De Palma,M. et al. (2008) Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell, 14, 299-311.
35. Dickson,P.V. et al. (2007) Continuous delivery of IFN-beta promotes sustained maturation of intratumoral vasculature. Mol. Cancer Res., 5, 531-542.
36. Parangi,S. et al. (1996) Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl Acad. Sci. USA, 93, 2002-2007.
37. Huss,W.J. et al. (2003) Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate, 54, 8-16.
38. Polnaszek,N. et al. (2003) Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res., 63, 5754-5760.
39. Asefa,B. et al. (2004) The interferon-inducible p200 family of proteins: A perspective on their roles in cell cycle regulation and differentiation. Blood Cells Mol. Dis., 32, 155-167.
40. Gil,J. et al. (2006) Regulation of the INK4b-ARF-INK4a tumour suppressor locus: All for one or one for all. Nat. Rev. Mol. Cell Biol., 7, 667-677.
41. Hobeika,A.C. et al. (1997) IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells. Oncogene, 14, 1165-1170.
42. Folkman,J. (1998) Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology, 139, 441-442.
43. Olumi,A.F. et al. (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res., 59, 5002-5011.
44. Belardelli,F. et al. (2002) Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev., 13, 119-134.
45. Naschberger,E. et al. (2008) Angiostatic immune reaction in colorectal carcinoma: Impact on survival and perspectives for antiangiogenic therapy. Int. J. Cancer, 123, 2120-2129.
46. Naschberger,E. et al. (2006) Human guanylate binding protein-1 is a secreted GTPase present in increased concentrations in the cerebrospinal fluid of patients with bacterial meningitis. Am. J. Pathol., 169, 1088-1099.
47. Naschberger,E. et al. (2005) Human guanylate binding protein-1 (hGBP-1) characterizes and establishes a non-angiogenic endothelial cell activation phenotype in inflammatory diseases. Adv. Enzyme Regul., 45, 215-227.
48. Naschberger,E. et al. (2004) Nuclear factor-kappaB motif and interferon-alpha- stimulated response element co-operate in the activation of guanylate-binding protein-1 expression by inflammatory cytokines in endothelial cells. Biochem. J., 379, 409-420.
49. Guenzi,E. et al. (2003) The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression. EMBO J., 22, 3772-3782.
50. Varambally,S. et al. (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell, 8, 393-406.
51. Shand,R.L. et al. (2006) Molecular biology of prostate-cancer pathogenesis. Curr. Opin. Urol., 16, 123-131.